Hims & Hers Health, Inc. (HIMS) Stock Analysis
Last updated Oct 27, 2026
Health Check
Last analyzed Oct 23, 2026
- Financial Health 35
- Profitability 70
- Business Quality 75
- Balance Sheet 35
- Cash Flow 80
Why this rating?
Health 61/100 — Good Quality
Worth tracking, but timing is mixed — not a clear setup yet.
Company overview
Hims & Hers Health, Inc. (HIMS) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Hims & Hers Health, Inc. 61/100 (Good Quality) due to high business quality, strong revenue growth, and elevated leverage.
Investment profile
- Quality High
- Growth Strong
- Balance Sheet Stretched
- Valuation Elevated
Financial highlights
Valuation
- Forward P/E 37.87
- PEG 2.52
- EV/Revenue 2.8
Profitability
- Revenue Growth 38.2%
- Gross Margin 69.5%
- Operating Margin -12.8%
- Net Margin -5.5%
- ROE -32.0%
Financial strength
- Cash $841.05M
- Debt $1.55B
- Net Cash $-705.19M
- Free Cash Flow $57.41M
- Current Ratio 0.93
Similar companies
Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- United Therapeutics Corporation Drug Manufacturers - Specialty & Generic UTHR$591.20 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- BioCryst Pharmaceuticals, Inc. Drug Manufacturers - Specialty & Generic BCRX$8.10 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Strong Entry Strong EntryTiming looks favorable across trend, momentum, valuation, support, and catalysts.
- Zoetis Inc. Drug Manufacturers - Specialty & Generic ZTS$78.23 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Neurocrine Biosciences, Inc. Drug Manufacturers - Specialty & Generic NBIX$146.00 74 Health 74 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Strong Entry Strong EntryTiming looks favorable across trend, momentum, valuation, support, and catalysts.
- Lantheus Holdings, Inc. Drug Manufacturers - Specialty & Generic LNTH$100.15 70 Health 70 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Trulieve Cannabis Corp. Drug Manufacturers - Specialty & Generic TRLV$10.67 64 Health 64 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Alkermes plc Drug Manufacturers - Specialty & Generic ALKS$44.32 62 Health 62 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Teva Pharmaceutical Industries Limited Drug Manufacturers - Specialty & Generic TEVA$40.39 60 Health 60 / 100
Solid fundamentals with some trade-offs across our health dimensions.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
FAQ
How Compound Radar scores and tracks Hims & Hers Health, Inc. (HIMS).